The risk increases significantly when Ozempic is used in combination with insulin or sulfonylureas
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
In the first phase, data were retrospectively collected from patient medical records from 2013 to 2023
There were studies that looked at using the 0.1% Estradiol and the 0.03% on the face and they found no systemic absorption
Intrauterine devices (IUDs), subdermal implants, and hormone injections bypass oral absorption and eliminate GLP-1 interaction concerns
